
|Videos|January 16, 2014
The Immunogenic Potential of Biosimilars: Should Health Care Providers Be Concerned?
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
Advertisement
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Federal Health Officials Scale Back Number of Recommended Vaccines for Children
2
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
3
GoodRx Expands Access to Oral GLP-1 Therapy With Semaglutide Pill Cash Pricing
4
Toothpaste Tablets Are Gaining Popularity—Here’s Where Pharmacists Fit In
5













































































































































































































